Navigation Links
Pfenex Reports Second Quarter 2014 Results and Provides Business Update
Date:8/29/2014

SAN DIEGO, Aug. 29, 2014 /PRNewswire/ -- Pfenex Inc. (NYSE MKT: PFNX), a clinical-stage biotechnology company engaged in the development of high-value and difficult to manufacture proteins including biosimilar therapeutics, today provided a business update and reported financial results for the second quarter ended June 30, 2014.

"With the successful completion of our initial public offering, we have the capital to continue to advance our biosimilar product candidates, derived from our proprietary protein expression platform," stated Bertrand C. Liang, chief executive officer of Pfenex. "We expect to complete the phase 1b/2a trial for our lead product candidate, PF582, a biosimilar to Lucentis, by the end of 2014 and initiate the phase 3 trial in mid-2015." 

Business Updates

  • On July 29, 2014 we closed our initial public offering.  Including the underwriters exercise of their option to purchase additional shares, 9,429,084 shares of common stock were sold in the offering for a total capital raise of approximately $52.6 million after underwriter fees and discounts but before deducting offering expenses.
  • With the close of our initial public offering, Pfenex expanded the leadership team through the addition of two new board members, William R. Rohn and Philip R. Schneider. Mr. Rohn joined the board as chairman and brings extensive biotech industry experience having served in managerial roles at Biogen IDEC, IDEC Pharmaceuticals and Adria Laboratories. Mr. Schneider also joined the board with broad industry experience through previous management positions with IDEC Pharmaceuticals and Syntex Pharmaceuticals.
  • Financial Highlights for the three months ended June 30, 2014

  • Total revenue for the second quarter of 2014 was $3.3 million compared to $2.3 million in the second quarter of 2013.
    The increase in revenue was due to an increase in activity related to our Px563L product candidate development under
    '/>"/>

  • SOURCE Pfenex Inc.
    Copyright©2014 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8

    Related biology technology :

    1. Pfenex Inc. Awards Glide Pharma Development Contract for a Solid Formulation of Recombinant Anthrax Vaccine
    2. Pfenex Inc. Awards Paragon Bioservices a Contract for cGMP Manufacturing of its Recombinant Protective Antigen (rPA), for Phase 1 Clinical Trial of its Anthrax Vaccine
    3. Pfenex Awarded Contract For Development Of Next Generation rPA-Based Anthrax Vaccine
    4. Discovery Labs Reports Third Quarter Financial Results and Progress on Lead Programs
    5. Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2011
    6. Interleukin Genetics Reports Third Quarter 2011 Financial Results
    7. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
    8. Nile Therapeutics Reports 2011 Third Quarter Financial Results
    9. Pharmasset Reports Fiscal Year End 2011 Financial Results
    10. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on November 15, 2011
    11. SeraCare Reports Fiscal Year 2011 and Fourth Quarter Financial Results
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:12/22/2014)... 2014 The Center for Professional ... technical training across the life sciences industry, has partnered ... (SCDM) to provide the organization's members with discounted classroom ... to the more than 350 sessions across 80 course ... off when registering for a public course ...
    (Date:12/22/2014)... 22, 2014  Alternative Energy & Environmental Solutions, ... signed a letter of intent to acquire BioTechPharma ... patented a nanotechnology-based development platform used to create ... rapid on-site collection and testing to identify infectious ... in an immediate, non-invasive and cost-effective manner. ...
    (Date:12/22/2014)... The American Journal of ... research, reviews and editorials addressing developments and pathways ... published a provocative article exploring the role of ... potential treatment of prostate cancer. , The ... the possibility that there could be a connection ...
    (Date:12/19/2014)... Tigard, OR and Hershey, PA (PRWEB) December 19, ... (OTC Pink: BJCT), a leading developer and manufacturer ... has entered into an agreement with Immunomic Therapeutics, ... Bioject’s Biojector®-2000 needle-free injection device with its LAMP™ ... receives an option for an exclusive Worldwide license ...
    Breaking Biology Technology:CfPIE Announces Partnership with the Society for Clinical Data Management 2CfPIE Announces Partnership with the Society for Clinical Data Management 3ALNE Announces Intention To Acquire BioTechPharma 2Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 2Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 3Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 4Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 2Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 3
    ... Dyadic International, Inc. (Pink Sheets: DYAI) ("Dyadic"), a leading-edge early-stage biotechnology ... long-term growth objectives: , , , ... ) , , , ... Anne E. Whitehead as Executive Director of Strategic Alliances . Ms. ...
    ... Ansell today announced the launch,of their new GAMMEX(R) Powder-Free glove with ... in, Perth, Australia . , , ... It is the first surgical glove which incorporates a proprietary,antimicrobial coating ... in the event of a breach during,surgery. , ...
    ... INDIANAPOLIS , May 3 ... to our life sciences strengths.  According to a new ... released today at the BIO International Conference in ... with specialized bioscience employment in three of the four ...
    Cached Biology Technology:Dyadic International Strengthens Management Team 2Dyadic International Strengthens Management Team 3Dyadic International Strengthens Management Team 4Dyadic International Strengthens Management Team 5Ansell Launches Worlds's First Antimicrobial Surgical Glove 2Indiana Continues to Make Its Mark as a Leading Life Sciences Center 2Indiana Continues to Make Its Mark as a Leading Life Sciences Center 3Indiana Continues to Make Its Mark as a Leading Life Sciences Center 4Indiana Continues to Make Its Mark as a Leading Life Sciences Center 5Indiana Continues to Make Its Mark as a Leading Life Sciences Center 6
    (Date:12/10/2014)... 9, 2014 CIE San Diego has launched ... the connective tissue that enhances care coordination among social ... share client-level information; earned a second $1 million grant ... serving seniors aging in community and; will be recognized ... 11 th 4-6p. CIE San Diego ...
    (Date:12/4/2014)... GARDENS, Fla. , Dec. 3, 2014 /PRNewswire/ ... solutions, today announced that its DigitalPersona ® ... fingerprint readers have been deployed throughout First Bank ... , South Carolina and ... in Southern Pines, North Carolina ...
    (Date:11/21/2014)... Nov. 20, 2014 Strict laws against distracted ... piloting the North American and European automotive sector towards ... gesture recognition systems that are intuitive and able to ... the industry. New analysis from Frost ... Market in Europe and ...
    Breaking Biology News(10 mins):Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 2Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 3Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 4First Bank Partners with Crossmatch to Increase Log In Security 2First Bank Partners with Crossmatch to Increase Log In Security 3Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 2Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 3Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 4
    ... free of charge for all holders of a valid ... access to the onsite press facilities, including a working ... will also be able to assist you in organising ... can register for free online at: http://www.eular.org/congress_press_registration.cfm ...
    ... researchers at North Carolina State University have found that ... intestinal birth defects may also inhibit the growth and ... chemical compounds created by NC State chemist Dr. Alex ... particular interest to her research: a compound that induced ...
    ... Indonesia has promised to become a world leader ... committed to a 26% reduction in greenhouse gas emissions ... 14% would have to come from reducing emissions from ... and other bodies are expected to raise total emission ...
    Cached Biology News:Compound useful for studying birth defects may also have anti-tumor properties 2Hotspots of carbon confusion in Indonesia threaten to warm the world more quickly 2Hotspots of carbon confusion in Indonesia threaten to warm the world more quickly 3Hotspots of carbon confusion in Indonesia threaten to warm the world more quickly 4Hotspots of carbon confusion in Indonesia threaten to warm the world more quickly 5
    ...
    Rat neural stem cell kits are intended for the in vitro growth and commitment to neuronal and glial lineage differentiation, of cultured fetal rat neural stem and progenitor cells expanded using FGF-...
    ... magnetic separator for six microtubes ... conjunction with the Captivate ferrofluid ... other magnetic particles and can ... tubes. Cell Biology Cell Separation ...
    Antibodies were affinity purified using epitopes specific to JLP immobilized on solid support....
    Biology Products: